Atara Biotherapeutics extends $9 million payment deadline to 2028

Atara Biotherapeutics Inc. (NASDAQ: ATRA) announced it amended an agreement with HealthCare Royalty to extend the due date of a $9 million cash payment from June 30, 2026 to January 1, 2028.

The payment relates to a milestone in the company's commercialization agreement with Pierre Fabre Medicament for tabelecleucel, Atara's T-cell immunotherapy. The original purchase and sale agreement with HealthCare Royalty was signed in December 2022.

As part of the amendment, Atara issued a warrant to HealthCare Royalty to purchase up to 400,000 shares of common stock at an exercise price of $0.0001 per share. The warrant has no expiration date and is exercisable immediately, subject to beneficial ownership limits.

"This flexibility allows us to focus on addressing the concerns in the latest CRL with the agency, supporting our partners, Pierre Fabre," said Cokey Nguyen, Atara's president and chief executive officer, referring to a Complete Response Letter from regulators.

Clarke Futch, chairman and chief executive officer at HealthCare Royalty, said the amendment provides time for Atara and Pierre Fabre to work with the FDA on a path to approval in the United States.

Tabelecleucel is approved in Europe for treating relapsed or refractory EBV-positive post-transplant lymphoproliferative disease, a rare form of lymphoma. The therapy is part of Atara's allogeneic T-cell immunotherapy platform targeting Epstein-Barr virus-related diseases.

The information is based on a company press release.

You May Also Be Interested In

• Lexaria receives $2.6M tax rebate from Australian R&D program
• Palo Alto Networks (PANW) call put ratio 1 call to 1.1 puts into quarter results
• Sonos launches OS 27 with AI control and two new products